

研究成果の刊行に関する一覧表レイアウト（参考）

書籍

著者氏名	論文タイトル名	書籍全体の編集者名	書籍名	出版社名	出版地	出版年	ページ
橋本亮太	第IX章 精神疾患「統合失調症」	門脇 孝, 小室 一成, 宮地 良樹	日常診療に活かす診療ガイドラインUP-TO-DATE	メディカルレビュー社	東京	2022	596-600
木田直也、橋本亮太	クロザピン療法	一般社団法人内科系学会社会保険連合	標準的医療説明－インフォームド・コンセントの最前線－	医学書院	東京	2021	243-4

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Yasui-Furukori N, Muraoka H, Hasegawa N, Ochi S, Numata S, Hori H, Hishimoto A, Onitsuka T, Ohi K, Hashimoto N, Nagasawa T, Takaesu Y, Inagaki T, Tagata H, Tsuboi T, Kubota C, Furihata R, Iga J I, Iida H, Miura K, Matsumoto J, Yamada H, Watanabe K, Inada K, Shimoda K, Hashimoto R.	Association between the examination rate of treatment-resistant schizophrenia and the clozapine prescription rate in a nationwide dissemination and implementation study.	Neuropsychopharmacol Rev	42(1)	3-9	2022
Kikuchi M, Nakazawa T, Kinoshita M, Yamamori H, Yasuda Y, Fujimoto M, Hashimoto R, Numata S.	Methylation Analysis in Monozygotic Twins with Treatment-Resistant Schizophrenia and Discordant Responses to Clozapine.	Front Psychiatry, section Schizophrenia	12	734606	2021

Imazu S, Hata T, Toyoda K, Kubo Y, Yamauchi S, Kinoshita S, Nishihara M, Inada K, Kanazawa T	Safety profile of clozapine: Analysis using national registry data in Japan.	J Psychiatr Res	141	116-23	2021
Ninomiya K, Saito T, Okochi T, Taniguchi S, Shimasaki A, Aoki R, Hata T, Muroshiroda T, Kanazawa T, Ikeda M, Iwata N.	Safety profile of clozapine: Analysis using national registry data in Japan	Transl Psychiatry.	11((1)	362	2021
Japanese Society of Neuropsychopharmacology.	Japanese Society of Neuropsychopharmacology: "Guideline for Pharmacological Therapy of Schizophrenia".	Neuropsychopharmacol Rev	41(3)	266-324	2021
Tsukiji M, Sasaki T, Nakata Y, Ota K, Aoki T, Hara K, Mamada T, Nakane J, Kogure M, Seki R, Idemoto K, Hashimoto T, Koishikawa H, Moriyama T, Suzuki T, Kanahara N, Ishii I, Iyo M, Niitsu T.	Risk factors for early-phase clozapine discontinuation: A nested case-control study.	Asian J Psychiatry.	62	102745	2021
Toyoda K, Hata T, Yamauchi S, Kinoshita S, Nishihara M, Uchiyama K, Inada K, Kanazawa T.	Clozapine Is Better Tolerated in Younger Patients: Risk Factors for Discontinuation from a Nationwide Database in Japan	Psychiatry Investigatio	18(2)	101-9	2021

<p>Ichihashi K, Kyo u Y, Hasegawa N, Yasui-Furukori N, Shimmizu Y, H ori H, Hashimoto N, Ide K, Imamu ra Y, Yamada H, Ochi S, Iga J, T akaesu Y, Ohi K, Tsuboi T, Iida H, Yamagata H, H ishimoto A, Hora i T, Usami M, Ma kinodan M, Nagas awa T, Komatsu H, Kido M, Murao ka H, Atake K, T akeshima M, Kubo ta C, Inagaki T, Tamai S, Kishim oto T, Furihata R, Matsumoto J, Miura K, Inada K, Watanabe K, K asai K, <u>Hashimoto R.</u></p>	<p>The characteristics of patients receiving psychotropic pro re n ata medication at dis charge for the treatm ent of schizophrenia and major depressive disorder: A nationwid e survey from the EGU IDE project.</p>	<p>Asian J Psych iatr,</p>	<p>69</p>	<p>103007</p>	<p>2022</p>
<p>Onitsuka T, Hira no Y, Nemoto K, Hashimoto N, Kus hima I, Koshiyam a D, Koeda M, Ta kahashi T, Noda Y, Matsumoto J, Miura K, Nakazaw a T, Hikida T, K asai K, Ozaki N, <u>Hashimoto R.</u></p>	<p>Trends in big data an alyses by multicenter collaborative transl ational research in p sychiatry..</p>	<p>Psychiatry Cl in Neurosci</p>	<p>76(1)</p>	<p>1-14</p>	<p>2022</p>
<p>Hashimoto N, Yas ui-Furukori N, H asegawa N, Ishik awa S, Numata S, Hori H, Iida H, F urukori H, Iida H, Ichihashi K, Fu rihata R, Murata A, Tsuboi T, Ta akeshima M, Kyou Y, Komatsu H, Ku bota C, Ochi S, Takaesu Y, Usami M, Nagasawa T, Hishimoto A, Miu ra K, Matsumoto J, Ohi K, Yamada H, Inada K, Wat anabe K, Shimoda K, <u>Hashimoto R.</u></p>	<p>Characteristics of di scharge prescriptions for patients with sc hizophrenia or major depressive disorder: Real-world evidence f rom the Effectiveness of Guidelines for Di ssemination and Educa tion (EGUIDE) psychia tric treatment projec t.</p>	<p>Asian J Psych iatr,</p>	<p>63</p>	<p>102744</p>	<p>2021</p>

<p>Numata S, Nakataki M, Hasegawa N, Takaesu Y, Tagakeshima M, Onitsuka T, Nakamura T, Edagawa R, Edano H, Miura K, Matsumoto J, Yasui-Furukori N, Kishimoto T, Hori H, Tsuboi T, Yasuda Y, Furihata R, Muraoka H, Ochi S, Nagasawa T, Kyou Y, Murata A, Katsumoto E, Ohi K, Hishimoto A, Inada K, Watanabe K, Hashimoto R.</p>	<p>Improvements in the degree of understanding the treatment guidelines for schizophrenia and major depressive disorder in a nationwide dissemination and implementation study.</p>	<p>Neuropsychopharmacol Rep,</p>	<p>41(2)</p>	<p>199-206</p>	<p>2021</p>
<p>Ito S, Matsumoto J, Sakai Y, Miura K, Hasegawa N, Yamamori H, Ishimaru K, Kim Y, Hashimoto R.</p>	<p>Positive association between insight and attitudes toward medication in Japanese patients with schizophrenia: Evaluation with the Schedule for Assessment of Insight (SAI) and the Drug Attitude Inventory - 10 Questionnaire (DAI-10).</p>	<p>Psychiatry Clin Neurosci,</p>	<p>75(5)</p>	<p>187-8</p>	<p>2021</p>